Angex is a biopharmaceutical company focusing on the discovery and development of proprietary small-molecule targeted therapies in oncology.
Angex founders are industry veterans with decades of seasoned R&D experience in US-based major pharmaceutical companies. Their R&D track records include two marketed drugs for oncology.
Angex has a focused approach on gnomically defined cancers as well as targeting biomarker-driven patient populations with clinically relevant mutations and acquired resistance.
Angex is developing a wide-range of drug candidates at the frontiers of immuno oncology, kinase inhibitors and epigenetics with the potential to reshape the landscape of cancer therapies and precision medicines. A number of programs are undergoing IND-enabling studies in preparation to file for clinical trials.
Email: angexpharma@angexpharmaceutical.com
Company Details
- Address
- North Brunswick, Nj 08902, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- Drug Discovery, Oncology, immuno oncology, kinase inhibitors, epigenetics, Solid Tumor, Liver Cancer, IND.
- HQ
- North Brunswick, NJ
Angex Pharmaceutical Inc Questions
Angex Pharmaceutical Inc's LinkedIn profile is https://www.linkedin.com/company/angex-pharmaceutical-inc
Angex Pharmaceutical Inc's industry is
Biotechnology Research
Angex Pharmaceutical Inc's top competitors are
Diva Pharmaceuticals, Inc.,
Starlight Therapeutics,
Zhejiang Fulai New Materials Co., Ltd,
Pion Inc.,
Angex - Angola Express, Lda,
Jucabio,
Biosortia, Inc.,
Angnet Fttx,
Ptc Therapeutics, Inc.,
Staidson Biopharma Inc.
Angex Pharmaceutical Inc's categories are Biotechnology Research
